Neurolief Secures Single Case Agreements with U.S. Payers for Proliv®Rx At-Home Depression Therapy
CORAL SPRINGS, Fla., Nov. 18, 2026
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.

![]()
Neurolief Secures Single Case Agreements with U.S. Payers for Proliv®Rx At-Home Depression Therapy
PR Newswire
CORAL SPRINGS, Fla., Nov. 18, 2026
Company accepting prescriptions from all clinicians whose patients are seeking insurance coverage, marking a key milestone toward broader payer access
CORAL SPRINGS, Fla., Nov. 18, 2026 /PRNewswire/ — Neurolief today announced that it has secured single case agreements with U.S. payers for Proliv®Rx, its FDA-approved at-home brain neuromodulation therapy for adults with major depressive disorder (MDD) who have not achieved satisfactory improvement from at least one antidepressant medication. With a commercial reimbursement pathway now in place, the company is accepting prescriptions from all clinicians whose patients are seeking insurance coverage.
Under a single case agreement, an insurer agrees to cover a specific treatment for an individual patient when the treatment is considered medically necessary, giving patients a way to access novel therapies that are not yet part of a health plan’s standard coverage policy.
“Securing single case agreements with U.S. payers is an important milestone in our strategy to expand access to Proliv Rx,” said Scott Drees, CEO of Neurolief. “It shows there is a viable path to commercial reimbursement, and we want to make that path as simple as possible for patients and their clinicians.
“Our team works directly with the providers and the payers on each patient’s behalf, from documenting medical necessity and submitting prior authorization requests to supporting appeals if a request is denied,” continued Drees. “Together with FDA approval and strong clinical outcomes, this brings us closer to reaching the many patients who have not found adequate relief with antidepressants alone.”
Proliv Rx is delivered through a structured, physician-supervised program of 8 to 16 weeks, with two 40-minute sessions a day completed at home. A connected digital platform supports remote oversight, onboarding, adherence monitoring and symptom tracking.
“For patients who do not respond adequately to antidepressants, accessing advanced treatment used to require repeated visits to specialized treatment centers,” said Owen Muir, M.D., chief medical officer of Neurolief. “Proliv Rx brings clinically validated therapy into the home under physician supervision. Expanding reimbursement turns breakthrough innovation into real-world access. This offers hope to patients who might otherwise continue to struggle despite standard-of-care approaches. Our payer partners recognize the difference this therapy can make based on the strength of our clinical data.”
The reimbursement milestone builds on the FDA approval of Proliv Rx and compelling clinical results from the pivotal MOOD study, a randomized, double-blind, sham-controlled, multicenter trial involving 124 adults with MDD who continued to experience significant symptoms despite antidepressant treatment. Remission was more than three times as common with active treatment as with sham at eight weeks (21.3% vs. 6.0%) and reached 31.7% after 16 weeks of active treatment. Among patients receiving active treatment, the proportion with severe or very severe depression fell from 81% at baseline to just 15% after 16 weeks, while the proportion with mild or no depression increased from 0% to 56%.
An estimated 21 million U.S. adults had at least one major depressive episode in the past year, according to the National Institute of Mental Health, and about one-third of people with MDD do not achieve an adequate response to antidepressant treatment. Advanced options such as transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT) and esketamine require repeated in-clinic visits, creating barriers for many patients, especially in rural and underserved areas.
Neurolief is pursuing a broader market-access strategy across commercial payers, health systems and the U.S. Department of Veterans Affairs (VA) to expand access to Proliv Rx.
About Proliv Rx
Proliv Rx is an FDA-approved prescription at-home brain neuromodulation therapy for adults with MDD who have not achieved an adequate response to at least one antidepressant medication. Based on External Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS), the non-invasive therapy uses three independent stimulation channels and six electrodes to stimulate branches of the occipital and trigeminal nerves across the forehead and back of the head, sending signals to brain networks involved in mood regulation without penetrating the skull. The treatment is prescribed and managed under physician supervision and self-administered by the patient at home, supported by a digital platform for remote monitoring.
About Neurolief
Neurolief is developing neuromodulation therapies for mental health and neurological disorders. The company is focused on bridging critical gaps in medical care by delivering clinically validated treatments that pair scientific rigor with scalable, real-world accessibility.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurolief-secures-single-case-agreements-with-us-payers-for-prolivrx-at-home-depression-therapy-302943428.html
SOURCE Neurolief Inc.



